Viviana García-Horton (Viviana Garcia-Horton)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 11

Top Topics

Clostridium Difficile

Glycemic Control

Top Venues

Infectious diseases and therapy

The mental health clinician

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy (2024)
Paul Feuerstadt, Jessica R Allegretti, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn Tillotson, Lindy L Bancke, Kerry LaPlante, Kevin W Garey, Sahil Khanna
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious diseases and therapy 13 (1) (2024)
Daniel O Claassen, Rajeev Ayyagari, Viviana García-Horton, Su Zhang, Sam Leo
Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. The mental health clinician 13 (5) (2023)
Daniel O Claassen, Rajeev Ayyagari, Viviana García-Horton, Su Zhang, Sam Leo
Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. The mental health clinician 13 (5) (2023)
Neal D Shore, Viviana García-Horton, Emi Terasawa, Rajeev Ayyagari, Jamie Partridge Grossman, Adrianus Reginald Waldeck
Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer. Future oncology (London, England) (2023)
Daniel O Claassen, Rajeev Ayyagari, Viviana García-Horton, Su Zhang, Sam Leo
Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. The mental health clinician 13 (5) (2023)
Daniel O Claassen, Rajeev Ayyagari, Viviana García-Horton, Su Zhang, Sam Leo
Predictors of persistence and adherence to deutetrabenazine among patients with Huntington disease or tardive dyskinesia. The mental health clinician 13 (5) (2023)